{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T17:09:36Z","timestamp":1764176976532,"version":"3.46.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"xingdian talent plan \"Famous Doctor Special Project\"","award":["2023Y0786"],"award-info":[{"award-number":["2023Y0786"]}]},{"name":"Kunming Medical University Student Innovation and Entrepreneurship Training Program Project","award":["RLMY20220018"],"award-info":[{"award-number":["RLMY20220018"]}]},{"name":"scientific and technological innovation team of accurate pathological diagnosis of pulmonary malignant tumor, Kunming Medical University","award":["CXTD202210"],"award-info":[{"award-number":["CXTD202210"]}]},{"name":"Yunnan Provincial University Science and Technology Project for Serving Key Industries","award":["FWCY-BSPY2024084"],"award-info":[{"award-number":["FWCY-BSPY2024084"]}]},{"name":"Graduate Innovation Fund of Kunming Medical University","award":["2024B026"],"award-info":[{"award-number":["2024B026"]}]},{"name":"Yunnan Provincial Department of Science and Technology-Kunming Medical University Joint Fund for Applied Basic Research","award":["202401AY070001-349"],"award-info":[{"award-number":["202401AY070001-349"]}]},{"name":"First-Class Discipline Team of Team of Kunming Medical University","award":["2024XKTDYS07"],"award-info":[{"award-number":["2024XKTDYS07"]}]},{"name":"the Regional Fund Project of the National Natural Science Foundation of China","award":["82360523"],"award-info":[{"award-number":["82360523"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03929-7","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:43:05Z","timestamp":1764171785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of potential bladder cancer drug targets through Mendelian randomization and molecular docking"],"prefix":"10.1007","volume":"16","author":[{"given":"Chengwei","family":"Bi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kexun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanlong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanpeng","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yapeng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunchao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"3929_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3929_CR2","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. JAMA. 2020;324:1980\u201391.","journal-title":"JAMA"},{"key":"3929_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2554-5","volume":"11","author":"Q Xiong","year":"2020","unstructured":"Xiong Q, Liu A, Ren Q, Xue Y, Yu X, Ying Y, et al. Cuprous oxide nanoparticles trigger reactive oxygen species-induced apoptosis through activation of erk-dependent autophagy in bladder cancer. Cell Death Dis. 2020;11:366.","journal-title":"Cell Death Dis"},{"key":"3929_CR4","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H von der Maase","year":"2005","unstructured":"von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602\u20138.","journal-title":"J Clin Oncol"},{"key":"3929_CR5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","volume":"30","author":"M De Santis","year":"2012","unstructured":"De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, et al. Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30:191\u20139.","journal-title":"J Clin Oncol"},{"key":"3929_CR6","doi-asserted-by":"publisher","first-page":"103795","DOI":"10.1016\/j.critrevonc.2022.103795","volume":"178","author":"V Ruiz de Porras","year":"2022","unstructured":"Ruiz de Porras V, Pardo JC, Etxaniz O, Font A. Neoadjuvant therapy for muscle-invasive bladder cancer: current clinical scenario, future perspectives, and unsolved questions. Crit Rev Oncol Hematol. 2022;178:103795.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3929_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102101","volume":"6","author":"A Kj\u00e6r","year":"2025","unstructured":"Kj\u00e6r A, Kristj\u00e1nsd\u00f3ttir N, Juul RI, Nordentoft I, Birkenkamp-Demtr\u00f6der K, Ahrenfeldt J, et al. Low T cell diversity associates with poor outcome in bladder cancer: a comprehensive longitudinal analysis of the T cell receptor repertoire. Cell Rep Med. 2025;6:102101.","journal-title":"Cell Rep Med"},{"key":"3929_CR8","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","volume":"29","author":"G Griffiths","year":"2011","unstructured":"Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171\u20137.","journal-title":"J Clin Oncol"},{"key":"3929_CR9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","volume":"87","author":"AG van der Heijden","year":"2025","unstructured":"van der Heijden AG, Bruins HM, Carrion A, Cathomas R, Comp\u00e9rat E, Dimitropoulos K, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines. Eur Urol. 2025;87:582\u2013600.","journal-title":"Eur Urol"},{"key":"3929_CR10","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ng.3314","volume":"47","author":"MR Nelson","year":"2015","unstructured":"Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47:856\u201360.","journal-title":"Nat Genet"},{"key":"3929_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54849-w","volume":"9","author":"AD Hingorani","year":"2019","unstructured":"Hingorani AD, Kuan V, Finan C, Kruger FA, Gaulton A, Chopade S, et al. Improving the odds of drug development success through human genomics: modelling study. Sci Rep. 2019;9:18911.","journal-title":"Sci Rep"},{"key":"3929_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16969-0","volume":"11","author":"AF Schmidt","year":"2020","unstructured":"Schmidt AF, Finan C, Gordillo-Mara\u00f1\u00f3n M, Asselbergs FW, Freitag DF, Patel RS, et al. Genetic drug target validation using Mendelian randomisation. Nat Commun. 2020;11:3255.","journal-title":"Nat Commun"},{"key":"3929_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1166","author":"C Finan","year":"2017","unstructured":"Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aag1166.","journal-title":"Sci Transl Med"},{"key":"3929_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrcardio.2017.78","volume":"14","author":"MV Holmes","year":"2017","unstructured":"Holmes MV, Ala-Korpela M, Smith GD. Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nat Rev Cardiol. 2017;14:577\u201390.","journal-title":"Nat Rev Cardiol"},{"key":"3929_CR15","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1001\/jama.2017.17219","volume":"318","author":"CA Emdin","year":"2017","unstructured":"Emdin CA, Khera AV, Kathiresan S. Mendelian Randomization. JAMA. 2017;318:1925\u20136.","journal-title":"JAMA"},{"key":"3929_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41569-020-00493-1","volume":"18","author":"MV Holmes","year":"2021","unstructured":"Holmes MV, Richardson TG, Ference BA, Davies NM, Davey Smith G. Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. Nat Rev Cardiol. 2021;18:435\u201353.","journal-title":"Nat Rev Cardiol"},{"key":"3929_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35871-w","volume":"8","author":"AF McRae","year":"2018","unstructured":"McRae AF, Marioni RE, Shah S, Yang J, Powell JE, Harris SE, et al. Identification of 55,000 replicated DNA methylation QTL. Sci Rep. 2018;8:17605.","journal-title":"Sci Rep"},{"key":"3929_CR18","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s41588-021-00913-z","volume":"53","author":"U V\u00f5sa","year":"2021","unstructured":"V\u00f5sa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet. 2021;53:1300\u201310.","journal-title":"Nat Genet"},{"key":"3929_CR19","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","volume":"613","author":"MI Kurki","year":"2023","unstructured":"Kurki MI, Karjalainen J, Palta P, Sipil\u00e4 TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613:508\u201318.","journal-title":"Nature"},{"key":"3929_CR20","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.34408","author":"G Hemani","year":"2018","unstructured":"Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-base platform supports systematic causal inference across the human phenome. Elife. 2018. https:\/\/doi.org\/10.7554\/eLife.34408.","journal-title":"Elife"},{"key":"3929_CR21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ije\/dyv080","volume":"44","author":"J Bowden","year":"2015","unstructured":"Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44:512\u201325.","journal-title":"Int J Epidemiol"},{"key":"3929_CR22","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/ije\/dyr036","volume":"40","author":"S Burgess","year":"2011","unstructured":"Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40:755\u201364.","journal-title":"Int J Epidemiol"},{"key":"3929_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-024-01097-6","author":"LAC Millard","year":"2024","unstructured":"Millard LAC, Davey Smith G, Tilling K. Using the global randomization test as a Mendelian randomization falsification test for the exclusion restriction assumption. Eur J Epidemiol. 2024. https:\/\/doi.org\/10.1007\/s10654-024-01097-6.","journal-title":"Eur J Epidemiol"},{"key":"3929_CR24","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1111\/biom.13735","volume":"79","author":"Z Liu","year":"2023","unstructured":"Liu Z, Ye T, Sun B, Schooling M, Tchetgen ET. Mendelian randomization mixed-scale treatment effect robust identification and estimation for causal inference. Biometrics. 2023;79:2208\u201319.","journal-title":"Biometrics"},{"key":"3929_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-57100-3","volume":"14","author":"B Chen","year":"2024","unstructured":"Chen B, Wang L, Pu S, Guo L, Chai N, Sun X, et al. Unveiling potential drug targets for hyperparathyroidism through genetic insights via Mendelian randomization and colocalization analyses. Sci Rep. 2024;14:6435.","journal-title":"Sci Rep"},{"key":"3929_CR26","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41586-021-03855-y","volume":"597","author":"Q Wang","year":"2021","unstructured":"Wang Q, Dhindsa RS, Carss K, Harper AR, Nag A, Tachmazidou I, et al. Rare variant contribution to human disease in 281,104 UK Biobank exomes. Nature. 2021;597:527\u201332.","journal-title":"Nature"},{"key":"3929_CR27","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. ClusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284\u20137.","journal-title":"OMICS"},{"key":"3929_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1758-4","volume":"20","author":"D Otasek","year":"2019","unstructured":"Otasek D, Morris JH, Bou\u00e7as J, Pico AR, Demchak B. Cytoscape automation: empowering workflow-based network analysis. Genome Biol. 2019;20:185.","journal-title":"Genome Biol"},{"key":"3929_CR29","doi-asserted-by":"publisher","first-page":"W214","DOI":"10.1093\/nar\/gkq537","volume":"38","author":"D Warde-Farley","year":"2010","unstructured":"Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38:W214-220.","journal-title":"Nucleic Acids Res"},{"key":"3929_CR30","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51:D638-d646.","journal-title":"Nucleic Acids Res"},{"key":"3929_CR31","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1093\/bioinformatics\/btv313","volume":"31","author":"M Yoo","year":"2015","unstructured":"Yoo M, Shin J, Kim J, Ryall KA, Lee K, Lee S, et al. DSigDB: drug signatures database for gene set analysis. Bioinformatics. 2015;31:3069\u201371.","journal-title":"Bioinformatics"},{"key":"3929_CR32","doi-asserted-by":"publisher","first-page":"D1388","DOI":"10.1093\/nar\/gkaa971","volume":"49","author":"S Kim","year":"2021","unstructured":"Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2021;49:D1388-d1395.","journal-title":"Nucleic Acids Res"},{"key":"3929_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01244","volume":"9","author":"J Zhang","year":"2019","unstructured":"Zhang J, Sun M, Hao M, Diao K, Wang J, Li S, et al. FAM53A affects breast cancer cell proliferation, migration, and invasion in a p53-dependent manner. Front Oncol. 2019;9:1244.","journal-title":"Front Oncol"},{"key":"3929_CR34","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202300306R","volume":"37","author":"B Diao","year":"2023","unstructured":"Diao B, Sun C, Yu P, Zhao Z, Yang P. LAMA5 promotes cell proliferation and migration in ovarian cancer by activating Notch signaling pathway. FASEB J. 2023;37:e23109.","journal-title":"FASEB J"},{"key":"3929_CR35","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.1158\/1078-0432.CCR-15-2664","volume":"22","author":"A Bartolini","year":"2016","unstructured":"Bartolini A, Cardaci S, Lamba S, Oddo D, Marchi\u00f2 C, Cassoni P, et al. BCAM and LAMA5 mediate the recognition between tumor cells and the endothelium in the metastatic spreading of KRAS-mutant colorectal cancer. Clin Cancer Res. 2016;22:4923\u201333.","journal-title":"Clin Cancer Res"},{"key":"3929_CR36","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1038\/sj.onc.1208356","volume":"24","author":"P Ji","year":"2005","unstructured":"Ji P, Agrawal S, Diederichs S, B\u00e4umer N, Becker A, Cauvet T, et al. Cyclin A1, the alternative A-type cyclin, contributes to G1\/S cell cycle progression in somatic cells. Oncogene. 2005;24:2739\u201344.","journal-title":"Oncogene"},{"key":"3929_CR37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1046\/j.1365-2141.2003.04569.x","volume":"123","author":"T Nakamaki","year":"2003","unstructured":"Nakamaki T, Hamano Y, Hisatake J, Yokoyama A, Kawakami K, Tomoyasu S, et al. Elevated levels of cyclin A1 and A (A2) mRNA in acute myeloid leukaemia are associated with increased survival. Br J Haematol. 2003;123:72\u201380.","journal-title":"Br J Haematol"},{"key":"3929_CR38","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-11-2392","volume":"18","author":"W Sun","year":"2012","unstructured":"Sun W, Zaboli D, Wang H, Liu Y, Arnaoutakis D, Khan T, et al. Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer. Clin Cancer Res. 2012;18:1082\u201391.","journal-title":"Clin Cancer Res"},{"key":"3929_CR39","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/his.12499","volume":"66","author":"E Munari","year":"2015","unstructured":"Munari E, Chaux A, Maldonado L, Comp\u00e9rat E, Varinot J, Bivalacqua TJ, et al. Cyclin A1 expression predicts progression in pT1 urothelial carcinoma of bladder: a tissue microarray study of 149 patients treated by transurethral resection. Histopathology. 2015;66:262\u20139.","journal-title":"Histopathology"},{"key":"3929_CR40","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejca.2016.08.007","volume":"67","author":"KC Huang","year":"2016","unstructured":"Huang KC, Yang J, Ng MC, Ng SK, Welch WR, Muto MG, et al. Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells. Eur J Cancer. 2016;67:152\u201363.","journal-title":"Eur J Cancer"},{"key":"3929_CR41","doi-asserted-by":"publisher","first-page":"151635","DOI":"10.1016\/j.acthis.2020.151635","volume":"122","author":"RM da Silva","year":"2020","unstructured":"da Silva RM, Santos JN, Uno M, Chammas R, Kulcsar MAV, Sant\u2019Anna LB, et al. CCNA1 gene as a potential diagnostic marker in papillary thyroid cancer. Acta Histochem. 2020;122:151635.","journal-title":"Acta Histochem"},{"key":"3929_CR42","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1111\/j.1349-7006.2009.01246.x","volume":"100","author":"L Wang","year":"2009","unstructured":"Wang L, Cao XX, Chen Q, Zhu TF, Zhu HG, Zheng L. DIXDC1 targets p21 and cyclin D1 via PI3K pathway activation to promote colon cancer cell proliferation. Cancer Sci. 2009;100:1801\u20138.","journal-title":"Cancer Sci"},{"key":"3929_CR43","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/mc.22290","volume":"55","author":"C Tan","year":"2016","unstructured":"Tan C, Qiao F, Wei P, Chi Y, Wang W, Ni S, et al. DIXDC1 activates the Wnt signaling pathway and promotes gastric cancer cell invasion and metastasis. Mol Carcinog. 2016;55:397\u2013408.","journal-title":"Mol Carcinog"},{"key":"3929_CR44","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/mc.22059","volume":"53","author":"Z Xu","year":"2014","unstructured":"Xu Z, Liu D, Fan C, Luan L, Zhang X, Wang E. DIXDC1 increases the invasion and migration ability of non-small-cell lung cancer cells via the PI3K-AKT\/AP-1 pathway. Mol Carcinog. 2014;53:917\u201325.","journal-title":"Mol Carcinog"},{"key":"3929_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-015-0273-2","volume":"15","author":"L Wang","year":"2015","unstructured":"Wang L, Tan C, Qiao F, Wang W, Jiang X, Lian P, et al. Upregulated expression of DIXDC1 in intestinal-type gastric carcinoma: co-localization with \u03b2-catenin and correlation with poor prognosis. Cancer Cell Int. 2015;15:120.","journal-title":"Cancer Cell Int"},{"key":"3929_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041491","author":"WR Lin","year":"2020","unstructured":"Lin WR, Yeh CT. GALNT14: an emerging marker capable of predicting therapeutic outcomes in multiple cancers. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21041491.","journal-title":"Int J Mol Sci"},{"key":"3929_CR47","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/nm1627","volume":"13","author":"KW Wagner","year":"2007","unstructured":"Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L\/TRAIL. Nat Med. 2007;13:1070\u20137.","journal-title":"Nat Med"},{"key":"3929_CR48","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1158\/0008-5472.CAN-08-4405","volume":"69","author":"R Wang","year":"2009","unstructured":"Wang R, Morris DS, Tomlins SA, Lonigro RJ, Tsodikov A, Mehra R, et al. Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer. Cancer Res. 2009;69:3810\u20138.","journal-title":"Cancer Res"},{"key":"3929_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1460275","volume":"15","author":"H Un","year":"2024","unstructured":"Un H, Wusimanjiang W, Zhan W, Zhang X, Li M, Lei J, et al. Understanding bladder cancer risk: Mendelian randomization analysis of immune cell and inflammatory factor influence. Front Immunol. 2024;15:1460275.","journal-title":"Front Immunol"},{"key":"3929_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1607098","volume":"16","author":"Z Xu","year":"2025","unstructured":"Xu Z, Yang J, Ma Y, Tao B, He Y, Wu J, et al. Exploring of bladder cancer immune-related genes and potential therapeutic targets based on transcriptomic data and Mendelian randomization analysis. Front Immunol. 2025;16:1607098.","journal-title":"Front Immunol"},{"key":"3929_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084557","author":"M Ro\u0161in","year":"2024","unstructured":"Ro\u0161in M, Kelam N, Juri\u0107 I, Racetin A, Ogorevc M, Corre B, et al. Syndecans, exostosins and sulfotransferases as potential synovial inflammation moderators in patients with hip osteoarthritis. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25084557.","journal-title":"Int J Mol Sci"},{"key":"3929_CR52","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s41417-024-00737-z","volume":"31","author":"Y Lei","year":"2024","unstructured":"Lei Y, Zhang R, Cai F. Role of MARK2 in the nervous system and cancer. Cancer Gene Ther. 2024;31:497\u2013506.","journal-title":"Cancer Gene Ther"},{"key":"3929_CR53","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/j.1349-7006.2006.00292.x","volume":"97","author":"NH Cho","year":"2006","unstructured":"Cho NH, Choi YP, Moon DS, Kim H, Kang S, Ding O, et al. Induction of cell apoptosis in non-small cell lung cancer cells by cyclin A1 small interfering RNA. Cancer Sci. 2006;97:1082\u201392.","journal-title":"Cancer Sci"},{"key":"3929_CR54","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.7150\/ijbs.84994","volume":"19","author":"W Chen","year":"2023","unstructured":"Chen W, Xu J, Wu Y, Liang B, Yan M, Sun C, et al. The potential role and mechanism of circRNA\/miRNA axis in cholesterol synthesis. Int J Biol Sci. 2023;19:2879\u201396.","journal-title":"Int J Biol Sci"},{"key":"3929_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-03113-x","volume":"16","author":"X Zhang","year":"2025","unstructured":"Zhang X, Yan H, Bie L, Xu Z, Yao X, Li Z, et al. The role of LAMA5 in breast cancer progression and its potential in immunotherapy. Discov Oncol. 2025;16:1387.","journal-title":"Discov Oncol"},{"key":"3929_CR56","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s12672-024-01331-3","volume":"15","author":"L Cheng","year":"2024","unstructured":"Cheng L, Qiu Z, Wu X, Dong Z. Evaluation of circulating plasma proteins in prostate cancer using Mendelian randomization. Discov Oncol. 2024;15:453.","journal-title":"Discov Oncol."},{"key":"3929_CR57","first-page":"4753","volume":"15","author":"A Refaat","year":"2018","unstructured":"Refaat A, Owis M, Abdelhamed S, Saiki I, Sakurai H. Retrospective screening of microarray data to identify candidate IFN-inducible genes in a HTLV-1 transformed model. Oncol Lett. 2018;15:4753\u20138.","journal-title":"Oncol Lett"},{"key":"3929_CR58","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.leukres.2016.09.011","volume":"50","author":"Y Ouyang","year":"2016","unstructured":"Ouyang Y, Zhong F, Wang Q, Ding L, Zhang P, Chen L, et al. DIXDC1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) via enhancing p-Akt in Non-Hodgkin\u2019s lymphomas. Leuk Res. 2016;50:104\u201311.","journal-title":"Leuk Res"},{"key":"3929_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.844542","volume":"13","author":"A Polewko-Klim","year":"2022","unstructured":"Polewko-Klim A, Zhu S, Wu W, Xie Y, Cai N, Zhang K, et al. Identification of candidate therapeutic genes for more precise treatment of esophageal squamous cell carcinoma and adenocarcinoma. Front Genet. 2022;13:844542.","journal-title":"Front Genet"},{"key":"3929_CR60","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s11684-017-0568-x","volume":"13","author":"X Cui","year":"2019","unstructured":"Cui X, Ma B, Wang Y, Chen Y, Shen C, Kuang Y, et al. Rdh13 deficiency weakens carbon tetrachloride-induced liver injury by regulating Spot14 and Cyp2e1 expression levels. Front Med. 2019;13:104\u201311.","journal-title":"Front Med"},{"key":"3929_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-85565-3","volume":"15","author":"S Li","year":"2025","unstructured":"Li S, Gui J, Karagas MR, Passarelli MN. Transcriptome-wide association study identifies genes associated with bladder cancer risk. Sci Rep. 2025;15:1390.","journal-title":"Sci Rep"},{"key":"3929_CR62","doi-asserted-by":"publisher","first-page":"7296","DOI":"10.1158\/1078-0432.CCR-07-0861","volume":"13","author":"J Yu","year":"2007","unstructured":"Yu J, Zhu T, Wang Z, Zhang H, Qian Z, Xu H, et al. A novel set of DNA methylation markers in urine sediments for sensitive\/specific detection of bladder cancer. Clin Cancer Res. 2007;13:7296\u2013304.","journal-title":"Clin Cancer Res"},{"key":"3929_CR63","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/mt.2012.269","volume":"21","author":"K Uchino","year":"2013","unstructured":"Uchino K, Takeshita F, Takahashi RU, Kosaka N, Fujiwara K, Naruoka H, et al. Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression. Mol Ther. 2013;21:610\u20139.","journal-title":"Mol Ther"},{"key":"3929_CR64","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1002\/tox.23949","volume":"39","author":"X Liu","year":"2024","unstructured":"Liu X, Qiu Z, Zhang X, Su Z, Yi R, Zou D, et al. Generalized machine learning based on multi-omics data to profile the effect of ferroptosis pathway on prognosis and immunotherapy response in patients with bladder cancer. Environ Toxicol. 2024;39:680\u201394.","journal-title":"Environ Toxicol"},{"key":"3929_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26280-1","volume":"12","author":"CS Storm","year":"2021","unstructured":"Storm CS, Kia DA, Almramhi MM, Bandres-Ciga S, Finan C, Hingorani AD, et al. Finding genetically-supported drug targets for Parkinson\u2019s disease using Mendelian randomization of the druggable genome. Nat Commun. 2021;12:7342.","journal-title":"Nat Commun"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03929-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03929-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03929-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T17:05:17Z","timestamp":1764176717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03929-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3929"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03929-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"type":"electronic","value":"2730-6011"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2172"}}